Lipidor Ab (LIPI) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Lipidor Ab (LIPI) has a cash flow conversion efficiency ratio of -0.130x as of June 2024. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr-2.11 Million ≈ $-227.39K USD) by net assets (Skr16.29 Million ≈ $1.75 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see LIPI market cap overview for the company's overall valuation and market capitalisation.
Lipidor Ab - Cash Flow Conversion Efficiency Trend (2016–2024)
This chart illustrates how Lipidor Ab's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Lipidor Ab Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Lipidor Ab ranked by their cash flow conversion efficiency. Explore earnings quality score of Lipidor Ab to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
PERFORMANCE SHIPP.
F:DS2
|
0.030x |
|
Caravelle International Group
NASDAQ:HTCO
|
0.505x |
|
Tai Twun Enterprise Co Ltd
TW:3432
|
-0.099x |
|
Catenon S.A
MC:COM
|
0.241x |
|
Magna Terra Minerals Inc
V:MTT
|
0.179x |
|
Lion Industries Corporation Bhd
KLSE:4235
|
-0.076x |
|
Smithson Investment Trust PLC
LSE:SSON
|
0.000x |
|
Indivior PLC
LSE:INDV
|
-0.612x |
Annual Cash Flow Conversion Efficiency for Lipidor Ab (2016–2024)
The table below shows the annual cash flow conversion efficiency of Lipidor Ab from 2016 to 2024. View current stock price of Lipidor Ab for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | Skr7.72 Million ≈ $831.01K |
Skr-16.08 Million ≈ $-1.73 Million |
-2.082x | -216.42% |
| 2023-12-31 | Skr-9.34 Million ≈ $-1.01 Million |
Skr-16.70 Million ≈ $-1.80 Million |
1.789x | +109.84% |
| 2022-12-31 | Skr2.15 Million ≈ $230.94K |
Skr-39.00 Million ≈ $-4.20 Million |
-18.174x | -5811.04% |
| 2021-12-31 | Skr43.52 Million ≈ $4.68 Million |
Skr-13.38 Million ≈ $-1.44 Million |
-0.307x | -28.15% |
| 2020-12-31 | Skr63.66 Million ≈ $6.85 Million |
Skr-15.27 Million ≈ $-1.64 Million |
-0.240x | +56.67% |
| 2019-12-31 | Skr26.83 Million ≈ $2.89 Million |
Skr-14.85 Million ≈ $-1.60 Million |
-0.554x | -185.21% |
| 2018-12-31 | Skr14.45 Million ≈ $1.55 Million |
Skr-2.81 Million ≈ $-301.86K |
-0.194x | +81.58% |
| 2017-12-31 | Skr3.48 Million ≈ $374.18K |
Skr-3.66 Million ≈ $-394.30K |
-1.054x | +76.02% |
| 2016-12-31 | Skr833.68K ≈ $89.72K |
Skr-3.66 Million ≈ $-394.30K |
-4.395x | -- |
About Lipidor Ab
Lipidor AB (publ), a pharmaceutical development company, engages in the development of drugs for the treatment of psoriasis, acne vulgaris, bacterial skin infections, and atopic dermatitis. The company develops AKP-01, which is in Phase III for the treatment of psoriasis; and preclinical stage products, such as AKP-02 for psoriasis, AKP-03 for bacterial skin diseases, and AKP-07 for atopic dermat… Read more